Aprea Therapeutics, Inc.
News
(4)April 2026
APRE files S-3 for large shareholders to sell up to 74 million shares
# 📄 What This Document Is 📜 This is an S-3 Registration Statement, a major SEC filing that tells investors exactly what shares are available and under what conditions. Unlike a typical earnings report, this document is focused entirely on the potential *sale* of company stock and warrants by exist
Aprea proposes reverse stock split for shareholders at 2026 annual meeting
# 🧾 What This Document Is 📄 This is a Preliminary Proxy Statement (PRE 14A), which is a highly technical document filed with the SEC. Essentially, it’s the official homework assignment for the company's shareholders. It informs you about the upcoming 2026 Annual Meeting of Stockholders and outline
Aprea Therapeutics, Inc. — 8-K Filing
# 🧾 What This Document Is This is a Form 8-K filing, which companies use to announce major events to investors. Attached is a press release announcing that Aprea Therapeutics has closed a **$30 million private funding round**. This isn't a regular stock sale to the public; it was a direct deal with
March 2026
Aprea Therapeutics, Inc. — 8-K Filing
# 🧾 What This Document Is This is an 8-K filing from **Aprea Therapeutics, Inc. (APRE)**. It contains the full legal contract (Exhibit 10.1) for a **private investment deal**. Essentially, the company is selling stock and warrants directly to a group of investors to raise money. This isn't a public
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.